However, by defining the mechanistic insights into how this oncogene initiates tumorigenesis (for example, through senescence bypass or apoptotic thresholding) and how it drives breast cancer pathogenesis, we could exploit real opportunities for the development of specific and effective treatments for TBX2 ‘addicted’, poor outcome breast cancers. Here, TBX2 is linked to breast cancer.